|
|
Volumn 317, Issue 5836, 2007, Pages 305-
|
|
Singapore firm abandons plans for stem cell therapies
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
INSULIN;
BIOTECHNOLOGY;
DIABETES MELLITUS;
DRUG MANUFACTURE;
FUNDING;
GOVERNMENT;
HEART FAILURE;
HEART MUSCLE CELL;
INVESTMENT;
MARKETING;
NETHERLANDS;
NOTE;
PRIORITY JOURNAL;
RESEARCH;
RETINA MACULA DEGENERATION;
SCIENTIST;
SINGAPORE;
SPINAL CORD INJURY;
STEM CELL TRANSPLANTATION;
TREATMENT PLANNING;
ARTICLE;
CONGESTIVE HEART FAILURE;
ECONOMICS;
EMBRYO RESEARCH;
EMBRYONIC STEM CELL;
ETHICS;
FINANCIAL MANAGEMENT;
HUMAN;
BIOTECHNOLOGY;
DIABETES MELLITUS;
EMBRYO RESEARCH;
EMBRYONIC STEM CELLS;
HEART FAILURE, CONGESTIVE;
HUMANS;
RESEARCH SUPPORT;
SINGAPORE;
|
|
EID: 34547134930
PISSN: 00368075
EISSN: 10959203
Source Type: Journal
DOI: 10.1126/science.317.5836.305 Document Type: Note |
|
Times cited : (6)
|
|
References (0)
|